Dossier
Earendil Labs
Coverage of Earendil Labs in the Nexus archive.
- Eli Lilly just placed a $40 million bet on the next injectable boom
Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.